The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.
Franziska Maria IppenChristopher A Alvarez-BreckenridgeBenjamin M KuterAlexandria L FinkIvanna V BihunMatthew LastrapesTristan PensonStephen P SchmidtGregory R WojtkiewiczJiangfang NingMegha SubramanianAnita Giobbie-HurderMaria Martinez-LageScott L CarterDaniel P CahillHiroaki WakimotoPriscilla K BrastianosPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The results of this study suggest that the brain-penetrant PI3K/mTOR targeting GDC-0084 is a promising treatment option for breast cancer brain metastases with dysregulated PI3K/mTOR signaling pathway conferred by activating PIK3CA mutations. A national clinical trial is planned to further investigate the role of this compound in patients with brain metastases.
Keyphrases
- brain metastases
- small cell lung cancer
- signaling pathway
- clinical trial
- cell proliferation
- pi k akt
- white matter
- epithelial mesenchymal transition
- protein kinase
- open label
- randomized controlled trial
- cancer therapy
- multiple sclerosis
- resting state
- oxidative stress
- young adults
- double blind
- blood brain barrier
- cerebral ischemia